Maplight Therapeutics

This study is testing a new drug called ML-007C-MA in 500 adults with schizophrenia to see if it is safe and works well over a full year. Participants either recently completed a related study or are new to the trial. The goal is to understand the long-term effects and tolerabili…

This study tests an experimental drug called ML-007C-MA to see if it can reduce hallucinations and delusions in people with Alzheimer's disease. About 300 participants aged 55 to 90 will receive either the drug or a placebo. The goal is to improve symptoms without aiming to cure …

This study looks at the long-term safety of an experimental drug called ML007C-MA for people with Alzheimer's disease who experience hallucinations and delusions. It is a 52-week open-label extension for 210 adults who completed a prior study. The goal is to see if the drug remai…

This study tests an experimental oral medication, ML-007C-MA, against a placebo in 300 adults hospitalized for a sudden worsening of schizophrenia symptoms. The goal is to see if the drug safely reduces psychosis severity, measured by a standard symptom scale. Participants must b…